Kala Bio Inc (KALA)

$0.34 +0.05 (17.35%)
Market Cap 237.40M
Revenue (ttm) 0.00
Net Income (ttm) -38.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -3.28
Volume 260,796,798
Avg Vol 1,369,986
Day's Range N/A - N/A
Shares Out 911.33M
Stochastic %K 35%
Beta -2.37
Analysts Hold
Price Target $1.50

Company Profile

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The comp...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 996 5252
Fax: 781 642 0399
Address:
1167 Massachusetts Avenue, Arlington, United States
OngoStockblogian
OngoStockblogian Mar. 11 at 6:02 PM
$KALA fart noises 💨
0 · Reply
OngoStockblogian
OngoStockblogian Mar. 11 at 6:02 PM
$KALA #squeeze
0 · Reply
OngoStockblogian
OngoStockblogian Mar. 11 at 6:01 PM
$KALA here we go!!!
0 · Reply
BlazingStocks
BlazingStocks Mar. 11 at 6:01 PM
$KALA - With the full rebrand of Researgency.ai now complete, the platform is live and ready for enterprise clients. Kala’s scientists, working alongside Younet’s AI engineering team, are building the Company’s first custom AI agent right now, with delivery expected in approximately 14 days. This is not a rebranding announcement — this is a go-to-market readiness signal. https://finance.yahoo.com/news/kala-bio-launches-revolution-biotech-103000840.html
0 · Reply
OngoStockblogian
OngoStockblogian Mar. 11 at 6:00 PM
$KALA ahahaha we ain’t done here!!
0 · Reply
Sam_hs
Sam_hs Mar. 11 at 6:00 PM
$KALA .29 is coming
0 · Reply
Basana09
Basana09 Mar. 11 at 6:00 PM
$KALA what’s everyone’s expectation in 14 days with this one? Good luck to all.
0 · Reply
Zackpedia
Zackpedia Mar. 11 at 5:59 PM
$KALA Down to .32! Support at .3.
0 · Reply
Easttenn988
Easttenn988 Mar. 11 at 5:57 PM
$KALA Still here 👊🏻👍
0 · Reply
Sam_hs
Sam_hs Mar. 11 at 5:56 PM
$KALA good luck if it goes back to .40 today
0 · Reply
Latest News on KALA
Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents

Mar 11, 2026, 11:18 AM EDT - 2 hours ago

Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents

Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates

Mar 11, 2026, 6:30 AM EDT - 7 hours ago

Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates

Stock Trend Capital Provides Younet AI Investment Update

Mar 9, 2026, 6:20 AM EDT - 2 days ago

Stock Trend Capital Provides Younet AI Investment Update

KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”

Mar 4, 2026, 6:30 AM EST - 7 days ago

KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”

KALA BIO Settles Approximately $10.6 million of Debt

Jan 5, 2026, 4:10 PM EST - 2 months ago

KALA BIO Settles Approximately $10.6 million of Debt

KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Dec 4, 2025, 10:45 AM EST - 3 months ago

KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday?

Sep 29, 2025, 12:00 PM EDT - 5 months ago

Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday?

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 8, 2025, 8:00 AM EDT - 7 months ago

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 6, 2025, 8:00 AM EDT - 7 months ago

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

Jul 9, 2025, 8:00 AM EDT - 8 months ago

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

KALA BIO to Present at Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 10 months ago

KALA BIO to Present at Jefferies Global Healthcare Conference

KALA BIO Announces Chief Executive Officer Transition

Feb 12, 2025, 8:00 AM EST - 1 year ago

KALA BIO Announces Chief Executive Officer Transition

KALA BIO Announces $10,750,000 Private Placement

Dec 30, 2024, 8:00 AM EST - 1 year ago

KALA BIO Announces $10,750,000 Private Placement

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 1 year ago

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 14, 2024, 4:05 PM EDT - 1 year ago

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

Feb 26, 2024, 8:00 AM EST - 2 years ago

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 19, 2024, 4:01 PM EST - 2 years ago

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 8:00 AM EST - 2 years ago

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 8:00 AM EDT - 2 years ago

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 4, 2023, 8:00 AM EDT - 2 years ago

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

KALA BIO to Participate in Upcoming Investor Conferences in August

Aug 2, 2023, 4:01 PM EDT - 2 years ago

KALA BIO to Participate in Upcoming Investor Conferences in August

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 19, 2023, 4:01 PM EDT - 2 years ago

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

Jun 2, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

Mar 27, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 8, 2023, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Mar 3, 2023, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Kala Pharma: Rare Eye Disease Biotech Lottery Ticket Based On Stem Cell Platform

Jan 19, 2023, 7:12 AM EST - 3 years ago

Kala Pharma: Rare Eye Disease Biotech Lottery Ticket Based On Stem Cell Platform

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Dec 30, 2022, 12:02 PM EST - 3 years ago

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Kala Pharmaceuticals Stock Continues To Soar: What's Going On? - Kala Pharmaceuticals (NASDAQ:KALA)

Dec 29, 2022, 8:30 AM EST - 3 years ago

Kala Pharmaceuticals Stock Continues To Soar: What's Going On? - Kala Pharmaceuticals (NASDAQ:KALA)

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Dec 28, 2022, 6:48 AM EST - 3 years ago

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Dec 27, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Nov 28, 2022, 4:02 PM EST - 3 years ago

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Nov 28, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 8, 2022, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Nov 1, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Kala Pharmaceuticals Announces Reverse Stock Split

Oct 20, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Reverse Stock Split

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Sep 6, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Aug 19, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Aug 18, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2022 Results - Earnings Call Transcript

Aug 12, 2022, 7:51 PM EDT - 3 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2022 Results - Earnings Call Transcript

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 11, 2022, 7:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Aug 4, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

Jul 11, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

Jun 2, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

Why Kala Pharmaceuticals Shares Are Rising Today

May 23, 2022, 10:17 AM EDT - 4 years ago

Why Kala Pharmaceuticals Shares Are Rising Today

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

May 23, 2022, 12:01 AM EDT - 4 years ago

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2022 Results - Earnings Call Transcript

May 16, 2022, 10:54 AM EDT - 4 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2022 Results - Earnings Call Transcript

OngoStockblogian
OngoStockblogian Mar. 11 at 6:02 PM
$KALA fart noises 💨
0 · Reply
OngoStockblogian
OngoStockblogian Mar. 11 at 6:02 PM
$KALA #squeeze
0 · Reply
OngoStockblogian
OngoStockblogian Mar. 11 at 6:01 PM
$KALA here we go!!!
0 · Reply
BlazingStocks
BlazingStocks Mar. 11 at 6:01 PM
$KALA - With the full rebrand of Researgency.ai now complete, the platform is live and ready for enterprise clients. Kala’s scientists, working alongside Younet’s AI engineering team, are building the Company’s first custom AI agent right now, with delivery expected in approximately 14 days. This is not a rebranding announcement — this is a go-to-market readiness signal. https://finance.yahoo.com/news/kala-bio-launches-revolution-biotech-103000840.html
0 · Reply
OngoStockblogian
OngoStockblogian Mar. 11 at 6:00 PM
$KALA ahahaha we ain’t done here!!
0 · Reply
Sam_hs
Sam_hs Mar. 11 at 6:00 PM
$KALA .29 is coming
0 · Reply
Basana09
Basana09 Mar. 11 at 6:00 PM
$KALA what’s everyone’s expectation in 14 days with this one? Good luck to all.
0 · Reply
Zackpedia
Zackpedia Mar. 11 at 5:59 PM
$KALA Down to .32! Support at .3.
0 · Reply
Easttenn988
Easttenn988 Mar. 11 at 5:57 PM
$KALA Still here 👊🏻👍
0 · Reply
Sam_hs
Sam_hs Mar. 11 at 5:56 PM
$KALA good luck if it goes back to .40 today
0 · Reply
Imarsh20
Imarsh20 Mar. 11 at 5:55 PM
$KALA and it still didn’t move
0 · Reply
BigDaddyStocks2021
BigDaddyStocks2021 Mar. 11 at 5:55 PM
$KALA somebody just filled $115,000 worth of shares
0 · Reply
Pennytwits
Pennytwits Mar. 11 at 5:53 PM
$KALA don't let them trick you. Keep your shares
1 · Reply
OngoStockblogian
OngoStockblogian Mar. 11 at 5:52 PM
$KALA got bought up easy
0 · Reply
Ozunoy
Ozunoy Mar. 11 at 5:52 PM
$KALA i could have sold around .50 cent ffs maybe i was too greedy
0 · Reply
noepsteintrades
noepsteintrades Mar. 11 at 5:51 PM
$KALA oh damn lower lol 😆 🤣
0 · Reply
Ozunoy
Ozunoy Mar. 11 at 5:51 PM
$KALA wtf
0 · Reply
WhenIBuyitgoesup
WhenIBuyitgoesup Mar. 11 at 5:51 PM
$KALA garbage
0 · Reply
Imarsh20
Imarsh20 Mar. 11 at 5:51 PM
$KALA oof
0 · Reply
Tnightmare
Tnightmare Mar. 11 at 5:50 PM
$KALA might go red 💀
0 · Reply
OngoStockblogian
OngoStockblogian Mar. 11 at 5:48 PM
$KALA ah!! The technicals are showing a brand new shape called wide bottomed U. Very bullish wide bottomed U
0 · Reply
noepsteintrades
noepsteintrades Mar. 11 at 5:47 PM
$KALA guys if you don't like this one move on.
0 · Reply